abrysvo: Clinical Trials

1 trial of abrysvo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Not yet recruiting 1

Follow abrysvo: new trials by email Literature Review of abrysvo trials Research Report on abrysvo

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
MKK900 60 µg, MKK900 120 µg, ABRYSVO® - Respiratory Syncytial Virus (RSV)
Phase 1Not yet recruitingMAXVAX Biotechnology Limited Liability Company1202026-04-012026-03-25

Sponsors

MAXVAX Biotechnology Limited Liability Company (1)

Countries

Australia (1)